ERBB2 and breast cancer: Although nanomedicine has been developed this year to target progesterone and estrogen receptors (PR and ER), human epidermal growth factor receptor 2 (HER2), and microRNA (miRNAs) and long chain non-coding RNAs, the incidence of BC remains high, with previous studies suggesting that the number of new cases worldwide will be 2,261,419 women in 2020, and this number is expected to increase to 30.2 million by 2040 [5, 6].